CONBA(SH:600572)2024-04-26 08:48Financial Performance - The company reported a total revenue of RMB 1.82 billion for Q1 2024, a decrease of 14.38% year-on-year[11] - Net profit attributable to shareholders was RMB 216.06 million, down 23.98% compared to the same period last year[6] - The net profit excluding non-recurring gains and losses was RMB 201.47 million, reflecting a decline of 23.57% year-on-year[6] - Total operating revenue for Q1 2024 was ¥1,824,245,153.97, a decrease of 14.4% compared to ¥2,130,542,570.91 in Q1 2023[38] - Net profit for Q1 2024 was ¥229,964,707.74, a decline of 29.3% from ¥324,873,847.25 in Q1 2023[38] - The total comprehensive income for Q1 2024 was approximately ¥229.72 million, down from ¥324.87 million in Q1 2023, reflecting a significant decline[47] - The basic and diluted earnings per share for Q1 2024 were both ¥0.084, compared to ¥0.111 in Q1 2023, indicating a decrease of 24.3%[47] - The net profit attributable to the parent company's shareholders for Q1 2024 was approximately ¥216.06 million, a decrease of 24% compared to ¥284.21 million in Q1 2023[47] Cash Flow - The cash flow from operating activities showed a significant increase of 94.58%, amounting to RMB 161.30 million[4] - Cash inflows from operating activities totaled approximately ¥1.57 billion in Q1 2024, down from ¥1.69 billion in Q1 2023, representing a decline of about 6.7%[49] - The net cash flow from operating activities for Q1 2024 was approximately ¥161.30 million, an increase of 94% compared to ¥82.90 million in Q1 2023[49] - Cash inflow from investment activities totaled CNY 97,559,173.08, down from CNY 175,580,000.00 in the previous year[58] - Total cash outflow from operating activities was CNY 159,699,729.76, down from CNY 178,077,727.57 year-over-year[58] Assets and Liabilities - Total assets at the end of the reporting period were RMB 11.31 billion, a slight increase of 0.64% from the previous year[4] - The company's total assets amounted to ¥11,310,399,054.43, compared to ¥11,238,241,513.01 in the previous period[34] - Total liabilities decreased to ¥3,843,386,689.12 from ¥3,888,598,821.58[34] - The total liabilities rose to CNY 2,534,820,722.88, up from CNY 1,885,989,647.80 at the end of 2023, indicating an increase of 34.4%[51] - The company's total equity decreased to CNY 5,950,904,630.90 as of March 31, 2024, down from CNY 6,058,104,268.30 at the end of 2023, a decline of 1.8%[51] Shareholder Information - The total number of common shareholders at the end of the reporting period was 104,928[19] - Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd. holds 587,278,040 shares, accounting for 22.85% of the total shares[19] - The company repurchased a total of 25,705,695 shares, representing 1.00% of the total share capital, with a total expenditure of RMB 119.527 million[21][25] - Zhejiang Traditional Chinese Medicine Health Industry Group plans to increase its shareholding by at least 2% and up to 4% of the total share capital within six months[25] - The report indicates that there are no changes in the top 10 shareholders due to margin trading or securities lending[23] Research and Development - Research and development expenses increased by approximately RMB 16 million, indicating a 35.68% rise due to intensified R&D efforts[15] - Research and development expenses increased to ¥59,379,920.51 in Q1 2024, up 35.7% from ¥43,764,872.95 in Q1 2023[38] - The company's R&D expenses for Q1 2024 were CNY 7,540,121.60, a decrease from CNY 9,917,307.24 in Q1 2023, showing a reduction of 24.0%[54] Operational Strategy - The company plans to continue focusing on the core business strategy of traditional Chinese medicine and health products amid market changes[11] - The company experienced a 33.08% increase in accounts receivable, attributed to improved collection efforts and adjustments in customer credit policies[15]